2018 In Review – Cardiovascular, Metabolic, Renal, and Hematologic Diseases
Decision Resources Group’s analysts looked back at the key cardiovascular, metabolic, renal, and hematological market events that shaped 2018. Below... In DRG Blog/ January, 2019 Snapshot of Chronic Heart Failure Disease Management
Understanding Patient Demographics, Treatment Pathways, and Physician Prescribing Behavior How is Chronic Heart Failure Treated Today? Chronic heart... In DRG Blog/ December, 2018 Obesity and NASH: The Bugs don’t Work. Or do They?
Insights on the Gut Microbiome, Obesity, and NAFLD: Part I The human gastrointestinal (GI) tract is home to trillions of microorganisms, often... In DRG Blog/ November, 2018 The Drugs don’t Work. Or do They?
The PROs and CONS of Prescription Weight Loss Medications World Obesity Day is on October 11, and it is a timely reminder of the obesity epidemic... In DRG Blog, Drug Watch/ October, 2018 CV Risk: Vascepa Doesn’t just REDUCE-IT, Vascepa Slashes it
I must admit it, I am surprised by the scale of the risk reduction that Amarin Corporation’s Vascepa (icosapent ethyl) has delivered in the REDUCE-... In DRG Blog, Drug Watch/ September, 2018 Does Bad News Mean the Blues for Bempedoic Acid?
Esperion Therapeutics’ lead candidate, bempedoic acid, a novel cholesterol-lowering agent, has made steady progress and could meet an important... In DRG Blog, Drug Watch/ May, 2018 Global NASH Congress 2018: Beyond the Biopsy
Currently, only liver biopsy can provide a definitive diagnosis of NASH. As such, it is required for clinical trials evaluating novel therapies and... In DRG Blog, Drug Watch/ March, 2018 The Obesity Market 2017: Year in Review
Overall, 2017 was not exactly a stellar year for the obesity drug market, with more downs than ups, and although the unmet need for novel drug... In DRG Blog, Drug Watch/ February, 2018 Global NASH Congress 2018: Regulators and the Race to Drug Approval
Non-alcoholic steatohepatitis (NASH) is fast becoming a highly competitive drug development race; the high prevalence of the disease, the substantial... In DRG Blog, Drug Watch/ February, 2018 The NASH Market 2017: Year in Review
Some substance was added to all the hype around non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) in 2017. New drug... In DRG Blog, Drug Watch/ February, 2018 The Dyslipidemia Market 2017: Year in Review
Although 2017 was not awash with exciting novel therapies or practice-changing research, the importance of managing lipid levels to reduce the risk of... In DRG Blog, Drug Watch/ February, 2018 The Highs and Lows of 2017 – Cardiovascular, Metabolic, Renal, and Hematologic Diseases
DRG cardiovascular, metabolic, renal, and hematologic (CMRH) disease experts have compiled their top ten market events in 2017. Events run the gamut... In DRG Blog, Drug Watch/ January, 2018 Bempedoic Acid: A Statin Equivalent for the Statin Intolerant
The statin class provided a major breakthrough for managing high cholesterol, a key modifiable risk factor for cardiovascular (CV) disease, and are... In DRG Blog, Drug Watch/ November, 2017 ACC.17: a roller coaster of results
ACC is done for another year, with a multitude of exciting trials presented, including FOURIER, EBBINGHAUS, SPIRE-1 and -2, ORION-1, and CARAT. There... In DRG Blog, Drug Watch/ March, 2017 Orion-1 at ACC.17: Stellar Results Could Make Inclisiran the New PCSK9 Star
A lot of the hype surrounding ACC.17 is due to the release of cardiovascular (CV) outcomes data for Repatha (evolocumab), Amgen’s PCSK9 inhibitor... In DRG Blog, Drug Watch/ March, 2017 Repatha’s FOURIER results: make or break or the same economic ache for PCSK9 inhibitors?
We are potentially on the brink of another massive leap forward in terms of cardiovascular (CV) disease prevention. The first of the late-breaking... In DRG Blog, Drug Watch/ March, 2017 Bypassing Regulatory Hurdles for Faster Access to New Drugs?... Potential Disaster!
Earlier this month saw President Trump call for an overhaul of the FDA and the way it approves drugs, in particular accelerating the drug approval... In DRG Blog, Drug Watch/ March, 2017 What is the ‘high-fat’ content on the ACC.17 menu?
High-fat diets are all the rage these days, and ACC.17 has some serious high-fat content on the menu for dyslipidemia devotees. Some of the fare... In DRG Blog, Drug Watch/ February, 2017 The Dyslipidemia Market 2016: Year in Review
Have you ever had that holiday experience, when you thought you were going to receive an amazing gift, but when the big day arrived you got socks?... In DRG Blog, Drug Watch/ December, 2016 The NASH Market 2016: Year in Review
Christmas is a time of giving, and non-alcoholic steatohepatitis (NASH) is one disease that keeps on giving. Not only is it highly prevalent and... In DRG Blog, Drug Watch/ December, 2016